Kyle Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kyle Chang has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Vilar
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, USA
34 shared publications - Patrick M. Lynch
University of Texas M. D. Anderson Cancer, Center
28 shared publications - Andrew Latchford
Polyposis Registry, St Mark's Hospital, Harrow, UK
27 shared publications - Angharad Walters
Hone Bio Limited, Science Creates Old Market, Midland Road, Bristol, BS2 0JZ
27 shared publications - Bilal Al-Sarireh
Department of Hepatobiliary and Pancreatic Surgery, Morriston Hospital, Swansea, UK
27 shared publications - Diantha Terlouw
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
27 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500287
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non–Small-Cell Lung Cancer in the Absence of Treatment
PURPOSE: Quantifying changes in circulating tumor DNA (ctDNA) during treatment can rapidly identify patients responding to therapy, but accurate interpretation requires an understanding of variability in ctDNA levels in the absence of treatment. This analysis of 360 patients with advanced epidermal growth factor receptor ( EGFR )–mutant non–small-cell lung cancer (NSCLC) characterized ctDNA level changes in paired pretreatment samples and evaluated factors associated with variability. METHODS: Screening and cycle 1, day 1 (C1D1) pretreatment samples from 132 previously untreated and 228 previously treated patients in the FLAURA and AURA3 trials, respectively, had ctDNA quantified using next-generation sequencing (Guardant360/GuardantOMNI NGS panel; mean variant allele frequency [VAF] or EGFR -mutant VAF) and droplet digital polymerase chain reaction (ddPCR, Biodesix) EGFR assays. RESULTS: In FLAURA and AURA3, ≥20% reductions in ctDNA levels (panel mean VAF) from screening to C1D1 occurred in 31/132 (23.5%) and 43/228 (18.9%) patients with paired pretreatment plasma samples, respectively, including ≥50% reductions in 12 (9.1%) and 23 (10.1%) patients, and 100% reductions (ctDNA clearance) in 0 and 5 (2.2%) patients. Background variability was not fully accounted for by intra-NGS or NGS-ddPCR technical variability or other potential sources of variability; larger changes were associated with low VAF and low cell-free DNA (cfDNA) input. CONCLUSION: Intrapatient ctDNA variability over time in EGFR- mutant advanced NSCLC includes changes that may confound interpretation of treatment activity, depending on the magnitude of change used to indicate molecular response. These findings demonstrate that evaluation of on-treatment changes must account for potential background variability, including technical variability because of factors such as cfDNA input level and tumor-related VAF, and that baseline samples should be obtained as close as possible to treatment initiation to minimize the impact of background variability.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500287
Open AccessVariability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non–Small-Cell Lung Cancer in the Absence of Treatment
PURPOSE: Quantifying changes in circulating tumor DNA (ctDNA) during treatment can rapidly identify patients responding to therapy, but accurate interpretation requires an understanding of variability in ctDNA levels in the absence of treatment. This analysis of 360 patients with advanced epidermal growth factor receptor ( EGFR )–mutant non–small-cell lung cancer (NSCLC) characterized ctDNA level changes in paired pretreatment samples and evaluated factors associated with variability. METHODS: Screening and cycle 1, day 1 (C1D1) pretreatment samples from 132 previously untreated and 228 previously treated patients in the FLAURA and AURA3 trials, respectively, had ctDNA quantified using next-generation sequencing (Guardant360/GuardantOMNI NGS panel; mean variant allele frequency [VAF] or EGFR -mutant VAF) and droplet digital polymerase chain reaction (ddPCR, Biodesix) EGFR assays. RESULTS: In FLAURA and AURA3, ≥20% reductions in ctDNA levels (panel mean VAF) from screening to C1D1 occurred in 31/132 (23.5%) and 43/228 (18.9%) patients with paired pretreatment plasma samples, respectively, including ≥50% reductions in 12 (9.1%) and 23 (10.1%) patients, and 100% reductions (ctDNA clearance) in 0 and 5 (2.2%) patients. Background variability was not fully accounted for by intra-NGS or NGS-ddPCR technical variability or other potential sources of variability; larger changes were associated with low VAF and low cell-free DNA (cfDNA) input. CONCLUSION: Intrapatient ctDNA variability over time in EGFR- mutant advanced NSCLC includes changes that may confound interpretation of treatment activity, depending on the magnitude of change used to indicate molecular response. These findings demonstrate that evaluation of on-treatment changes must account for potential background variability, including technical variability because of factors such as cfDNA input level and tumor-related VAF, and that baseline samples should be obtained as close as possible to treatment initiation to minimize the impact of background variability.
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Methylation TF Results by Timepoint
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Methylation TF Results by Timepoint
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Forest Plot analysis for percentage TF change threshold determination
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Forest Plot analysis for percentage TF change threshold determination
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Strobe diagram showing inclusion and exclusion for patient samples from the RADIOHEAD study in which successful samples passed all QC metrics and delivered a TF result. Chemo, chemotherapy.
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Strobe diagram showing inclusion and exclusion for patient samples from the RADIOHEAD study in which successful samples passed all QC metrics and delivered a TF result. Chemo, chemotherapy.
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A–D, Longitudinal assessment of TF predicts ICI benefit in a pan-solid tumor cohort (n = 521; patients in whom rwPFS or rwOS event occurred before the reindex date were excluded where indicated). A, Kaplan–Meier analysis comparing the rwPFS of MR at any timepoint [NR (95% CI, NR–NR)] vs. nMR at all timepoints [3.93 months (95% CI, 3.33–4.40); n = 513]. B, Forest plot for CPH model for rwPFS with a HR of 0.24 (0.19–0.315) for MR vs. nMR (n = 513). C, Kaplan–Meier analysis comparing the rwOS of MR at any timepoint vs. nMR at all timepoints [NR (95% CI, NR–NR) vs. 7.166 months (95% CI, 5.73–9.10; n = 520)]. D, Forest plot for CPH model for rwOS with a HR of 0.28 (0.21, 0.38) for MR vs. nMR (n = 520).
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A–D, Longitudinal assessment of TF predicts ICI benefit in a pan-solid tumor cohort (n = 521; patients in whom rwPFS or rwOS event occurred before the reindex date were excluded where indicated). A, Kaplan–Meier analysis comparing the rwPFS of MR at any timepoint [NR (95% CI, NR–NR)] vs. nMR at all timepoints [3.93 months (95% CI, 3.33–4.40); n = 513]. B, Forest plot for CPH model for rwPFS with a HR of 0.24 (0.19–0.315) for MR vs. nMR (n = 513). C, Kaplan–Meier analysis comparing the rwOS of MR at any timepoint vs. nMR at all timepoints [NR (95% CI, NR–NR) vs. 7.166 months (95% CI, 5.73–9.10; n = 520)]. D, Forest plot for CPH model for rwOS with a HR of 0.28 (0.21, 0.38) for MR vs. nMR (n = 520).
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A and B, Candidate thresholds for TF change indicating MR and nMR among the patients in whom either T0 or T1 were quantifiable (n = 459). A, Forest plot for various TF changes (B) Kaplan–Meier analysis of rwPFS by select candidate thresholds across the full dataset. Log-rank test between groups: 100% vs. any decrease, P < 0.005; 80% decrease vs. any decrease, P = 0.01; 100% decrease vs. 80% decrease, P = 0.04; 100% decrease vs. any increase, P < 0.005; 80% decrease vs. any increase, P < 0.005; any decrease vs any increase, P < 0.005. c-index, concordance index.
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
A and B, Candidate thresholds for TF change indicating MR and nMR among the patients in whom either T0 or T1 were quantifiable (n = 459). A, Forest plot for various TF changes (B) Kaplan–Meier analysis of rwPFS by select candidate thresholds across the full dataset. Log-rank test between groups: 100% vs. any decrease, P < 0.005; 80% decrease vs. any decrease, P = 0.01; 100% decrease vs. 80% decrease, P = 0.04; 100% decrease vs. any increase, P < 0.005; 80% decrease vs. any increase, P < 0.005; any decrease vs any increase, P < 0.005. c-index, concordance index.
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Sensitivity analysis used to demonstrate impact of time ranges on longitudinal monitoring analysis
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Sensitivity analysis used to demonstrate impact of time ranges on longitudinal monitoring analysis
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Real-world outcomes of patients with TF below LOQ at both timepoints
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Real-world outcomes of patients with TF below LOQ at both timepoints
- Open Access
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Successful samples by cancer type and timepoint
- 20 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Successful samples by cancer type and timepoint